OncoGenex Pharmaceuticals

OncoGenex’s Spruce trial open for enrollment

Tuesday, August 6, 2013 10:30 AM

OncoGenex Pharmaceuticals has initiated the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled phase II trial evaluating OGX-427, a heat shock protein 27 (Hsp27) inhibitor, in patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

More... »

OncoGenex completes phase II enrollment

Wednesday, July 24, 2013 12:35 PM

OncoGenex Pharmaceuticals has completed enrollment in Borealis-1, a company-sponsored, randomized, placebo-controlled phase II trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

More... »

OncoGenex initiates trial in advanced squamous cell lung cancer

Thursday, May 30, 2013 01:21 PM

OncoGenex Pharmaceuticals plans initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label phase II trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.

More... »

OncoGenex to initiate phase II trial of OGX-427 in non-squamous NSCLC

Friday, April 12, 2013 12:17 PM

OncoGenex Pharmaceuticals, a biopharmaceutical company, plans to initiate an investigator-sponsored, randomized, double-blind, placebo-controlled phase II study, Spruce, evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). The trial will investigate whether adding OGX-427 to carboplatin and pemetrexed therapy can extend progression-free survival (PFS) outcomes.

More... »

OncoGenex prices $50 million public offering

Friday, March 16, 2012 04:32 PM

OncoGenex Pharmaceuticals, a biopharmaceutical company dedicated to new cancer therapies, has priced an underwritten public offering of 4,165,000 shares of its common stock at a purchase price of $12.00 per share. 

More... »

OncoGenex reports promising preclinical cancer data

Monday, March 5, 2012 06:09 AM

OncoGenex Pharmaceuticals’ compound OGX-427 shows potential for augmenting anti-cancer therapies and delay tumor progression.

More... »

Phase I study of OGX-427 shows evidence of activity in bladder cancer

Tuesday, February 7, 2012 08:28 AM

OncoGenex Pharmaceuticals has announced preliminary results from an investigator-sponsored phase I study of patients with superficial bladder cancer with its investigational compound OGX-427, designed to inhibit the production of Hsp27.

More... »

Results of OncoGenex phase I/II Custirsen trial published

Friday, January 6, 2012 09:32 AM

OncoGenex Pharmaceuticals has reported results of a phase I/II study to determine the effectiveness of its investigational compound custirsen in conjunction with a gemcitabine/platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC).

More... »